Celloram Inc.

Celloram Inc. is a preclinical stage company founded in 2018. Our team of experienced leaders and scientists share a passion for improving the health and well-being of patients and families affected by cancer and chronic disease. Celloram has a deep sense of social responsibility. We are dedicated to the community in which we reside and work, and where we honor our commitment to promote diversity by inspiring, educating and developing the next generation of scientists and leaders. Celloram now leverages its key discoveries to develop unique forms of cell therapy and small molecule therapeutics that harness our body’s own unique potential to heal and battle chronic illnesses including cancer, autoimmune disease, chronic inflammatory and metabolic disorders. Our mission and vision stem from our strong belief in the potential of new, less toxic therapies with the power to ignite our body’s self-healing process. With an ideal location at University Circle, Cleveland, OH, Celloram has benefited greatly from partnerships with health care leaders at two of the nation’s leading academic medical centers, including Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center. Supported by a highly motivated and dedicated group of partners and investors, Celloram has developed a pipeline of four unique therapeutics: Sopprimerex, Protexi, NOVS-100, and CLM-022. These cutting-edge therapies are in distinct phases of preclinical development and are rapidly advancing through essential steps that will position each core asset for entry into clinical trials and evaluation by the FDA. Our team at Celloram is committed to sharing our discoveries and advancing them for the benefit of human health.